Barrett Allan - Encinitas CA, US Chi-Kin Chow - Brownsburg IN, US Ling Liu - Carmel IN, US Jirong Lu - Carmel IN, US Jonathan Wendell Tetreault - Indianapolis IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
C07K 16/24
US Classification:
5303873, 53038823
Abstract:
Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful in particular for treating autoimmune, inflammatory, cell proliferative and developmental disorders.
Barrett Allan - Encinitas CA, US Chi-Kin Chow - Brownsburg IN, US Ling Liu - Carmel IN, US Jirong Lu - Carmel IN, US Jonathan Wendell Tetreault - Indianapolis IN, US Ying Tang - San Diego CA, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 39/395 C07K 16/24
US Classification:
4241451, 4241331, 4241581, 5303873, 53038823
Abstract:
Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful in particular for treating autoimmune, inflammatory, cell proliferative and developmental disorders.
Julian Davies - La Jolla CA, US Ling Liu - Carmel IN, US Jirong Lu - Carmel IN, US Peter Edward Vaillancourt - Del Mar CA, US Mark Andrew Wortinger - Greenwood IN, US Wei Zeng - Carmel IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
C07K 16/00
US Classification:
5303871, 5303888
Abstract:
Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met.
Julian Davies - La Jolla CA, US Ling Liu - Carmel IN, US Jirong Lu - Carmel IN, US Peter Edward Vaillancourt - Del Mar CA, US Mark Andrew Wortinger - Greenwood IN, US Wei Zeng - Carmel IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 39/395
US Classification:
4241301, 4241411, 4241431, 4241551
Abstract:
Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met.
Multifunctional Antibodies Binding To Egfr And Met
- Indianapolis IN, US Barrett ALLAN - Encinitas CA, US Ling LIU - Carmel IN, US Jirong LU - Carmel IN, US Ying TANG - San Diego CA, US Sheng-Hung Rainbow TSCHANG - Carmel IN, US Pia Pauliina YACHI - San Diego CA, US
International Classification:
C07K 16/40 C07K 16/28
Abstract:
Provided are multifunctional antibodies, and/or antigen-binding fragments, that bind to, and inhibit the activity of, both human epidermal growth factor receptor (EGFR) and MET, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by EGFR and MET.
- Indianapolis IN, US Julian Davies - La Jolla CA, US Irene Jennifer Denning - San Diego CA, US Ling Liu - Carmel IN, US Jirong Lu - Carmel IN, US Peter Edward Vaillancourt - Del Mar CA, US
International Classification:
C07K 16/32 G01N 33/574
US Classification:
4241391, 5303879, 435 723
Abstract:
The present invention relates to antibodies, or antigen-binding fragments thereof, that bind to the extracellular domain of human c-Met, compositions and kits comprising such c-Met antibodies, or antigen-binding fragments thereof, and methods of using the same for detection of human c-Met that aid in identifying patients with tumors expressing or overexpressing human Met and/or improving their treatment response with anti-c-Met therapeutics.
Julian Davies - La Jolla CA, US Ling Liu - Carmel IN, US Jirong Lu - Carmel IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
G01N 33/573
US Classification:
435 74, 5303879, 5303913, 5303873
Abstract:
Provided is a monoclonal antibody, or antigen-binding fragment thereof that binds to c-Met. Such antibodies, or antigen-binding fragments thereof, are useful in in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting cell surface c-Met receptor levels for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens in patients harboring tumors in which c-Met is implicated in pathogenesis.
UtrechtSenior Programmer at Accenture Technology Solution... Experienced in EAI middleware development and implementation, certified in TIBCO BusinessWorks5.2,familiar with WebMethods, SonicMQ, WebSphere.
At Cacharel, where the Chinese duo Ling Liu and Dawei Sun were showing their second collection, the focus was on coats, warm outfits in wool or felt, and sensual knit dresses that wrapped up around the neck.